Home
About
UNITE4TB (academia and industry united innovation and treatment for tuberculosis) is a public-private partnership with representation from academic institutions, small- and medium-sized enterprises (SMEs), public organizations, and pharmaceutical companies.
Over the course of 7 years (2021-2028), the consortium will be active in approximately 40 trial sites on four continents (Europe, Asia, Africa and South America), with the goal of delivering novel phase 2 clinical trials that will accelerate the development of new TB drugs and regimens. Achieving this goal will facilitate the fulfillment of one of the main unmet needs in the TB field: better-tolerated drug regimens of shorter duration that can be deployed to tackle tuberculosis across various drug-resistance patterns and co-morbidities.